Literature DB >> 11475729

[Study on treatment of blood stasis syndrome of chronic prostatitis using prostatitis decoction and its extract capsule].

Y Zhang1, Y Liu.   

Abstract

OBJECTIVE: To test and verify the effects of prostatitis decoction and its capsule on the treatment of chronic prostatitis with blood stasis Syndrome, and its therapeutic mechanism.
METHODS: Five hundred and sixty-one Patients were treated for 2 months, decoction group 322 cases, and capsule group 239 cases. As control group, 95 cases were treated with Qianliekang tablets. Expressed prostatic secretion(EPS)-pH and Zn content were measured before and after treatment. Observation on hemorheology and microcirculation disturbance with animal experiments were conducted.
RESULTS: The cure rate of Prostatitis decoction and capsule groups was 65.8%, and 54.4% respectively, that of control group was only 17.9%. EPS-pH and Zn were markedly improved after Prostatitis decoction treatment. Experimental work revealed that Prostatitis decoction and its capsule had lowered the whole blood viscosity, thrombocyte adhesiveness rate and dry weight of thrombus in blood stasis rabbit model; and on rats model of microcirculation disturbance caused by adrenalin, the Prostatitis decoction and its capsules had obviously delayed the occurrence of reduction and stopping of blood flow in arterioles.
CONCLUSION: Prostatitis decoction (capsule) was effective in treating chronic prostatitis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 11475729

Source DB:  PubMed          Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi        ISSN: 1003-5370


  2 in total

1.  Complementary and alternative medicine for chronic prostatitis/chronic pelvic pain syndrome.

Authors:  Jillian L Capodice; Debra L Bemis; Ralph Buttyan; Steven A Kaplan; Aaron E Katz
Journal:  Evid Based Complement Alternat Med       Date:  2005-10-10       Impact factor: 2.629

2.  Phytotherapy and other alternative forms of care for the patient with prostatitis.

Authors:  Daniel A Shoskes
Journal:  Curr Urol Rep       Date:  2002-08       Impact factor: 2.862

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.